Social Capital Suvretta Holdings Corp. IV
DNAD
NASDAQ Capital Market10.34
USD
-0.01
- -
CIK
0001850272
CUSIP
G8253Y105
Return %
Stock
S&P500
1Y
6.05
26.84
3Y
2.38
77.03
5Y
2.38
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chamath Palihapitiya
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2850 West Horizon Ridge Parkway Henderson NV United States of America 89052
- IPO Date
- Jun 30, 2021
- CIK
- 0001850272
- Similar Companies
- Business
- Social Capital Suvretta Holdings Corp. IV (DNAD) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant current operations; it focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, particularly targeting the biotechnology sector, including areas such as immunology and inflammatory diseases. The company provides no core products or services beyond its SPAC structure, which facilitates public market access for private targets through sponsor-led capital raising and trust account management for investor protection. Incorporated in 2021 and headquartered in Henderson, Nevada, it was founded by Chamath Palihapitiya, CEO and Chairman of Social Capital, and Kishen C. Mehta, President and Director from Suvretta Capital, as part of a series of biotech-focused SPACs (DNAA through DNAD); it priced an upsized initial public offering of 22 million Class A ordinary shares at $10.00 per share in June 2021, raising $220 million underwritten by Morgan Stanley. As of late 2025, the company remains pre-combination with no announced business merger, acquisition, or strategic alliance in the last 1-2 years, continuing to seek biotechnology targets amid a stabilizing SPAC market emphasizing quality deals; its market capitalization stands around $330 million with low trading volume and no dividends. It serves investors seeking exposure to high-growth biotech opportunities via the SPAC vehicle, operating principally in the United States with a focus on North American-listed public markets.